| NCT ID | NCT05580614 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Florida |
| Condition | OCD |
| Study Type | INTERVENTIONAL |
| Enrollment | 56 participants |
| Start Date | 2022-06-27 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 56 participants in total. It began in 2022-06-27 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In the proposed investigation, the investigator will develop pilot data for the use of tVNS (transcutaneous vagal nerve stimulation) to enhance efficacy of exposure and response prevention therapy (ERP) to improve treatment success in patients with OCD. This data will include tolerability information from therapists and patients with OCD, effect sizes on real world clinical outcomes for the combinatory treatment, and mechanistic data on brain changes associated with treatment.
Eligibility Criteria
Inclusion Criteria: * Adults between the ages of 18 and 55 * Meet DSM-5 criteria for OCD, based on a structured clinical interview and who have a YBOCS score of 15 or higher, indicating at least moderate OCD severity * Participants must be willing and able to provide informed consent. Exclusion Criteria: * Participants with major neurological conditions, autism spectrum disorder, psychosis, major uncorrected sensory deficit, and severe medical disease that may be associated with neurological effects. * People with an active eating disorder that requires treatment, but we will not exclude people who are in remission. * Current illicit or prescription drug abuse * Participants who are receiving pharmacotherapy for their OCD or for other psychiatric disorders will not be excluded * No medication changes will be allowed during the study, and participants must be on stable doses of medications for at least 6 weeks prior to entering the study. Prior ERP treatment (at least 12 months removed) is acceptable
Contact & Investigator
John Williamson, PhD
PRINCIPAL INVESTIGATOR
University of Florida
Frequently Asked Questions
Who can join the NCT05580614 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying OCD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05580614 currently recruiting?
Yes, NCT05580614 is actively recruiting participants. Contact the research team at laura.jones@ufl.edu for enrollment information.
Where is the NCT05580614 trial being conducted?
This trial is being conducted at Gainesville, United States.
Who is sponsoring the NCT05580614 clinical trial?
NCT05580614 is sponsored by University of Florida. The principal investigator is John Williamson, PhD at University of Florida. The trial plans to enroll 56 participants.